Summary
Becton Dickinson & Co. (BDX) reported its fiscal second-quarter 2012 results, showcasing modest revenue growth driven by its Medical and Diagnostics segments, partially offset by softer performance in the Biosciences segment. Overall revenue increased by 3.6% year-over-year, attributed to volume increases in medical devices and laboratory equipment, alongside contributions from recent acquisitions. However, the company faced headwinds from pricing pressures in the U.S. market and within certain product lines, as well as increased raw material costs. Financially, BDX maintained a strong liquidity position, with significant cash flow from operations. The company continued its commitment to shareholder returns through share repurchases and dividend payments. A notable event was the acquisition of KIESTRA Lab Automation BV, which is expected to bolster the Diagnostics segment's lab automation solutions. Looking ahead, BDX anticipates ongoing economic challenges and pricing pressures but remains focused on strategic investments in R&D, geographic expansion, and new product development to drive future growth.
Financial Highlights
50 data points| Revenue | $1.93B |
| Cost of Revenue | $941.18M |
| Gross Profit | $987.78M |
| R&D Expenses | $116.75M |
| SG&A Expenses | $487.69M |
| Operating Expenses | $1.55B |
| Operating Income | $383.33M |
| Interest Expense | $35.14M |
| Net Income | $291.03M |
| EPS (Basic) | $1.41 |
| EPS (Diluted) | $1.39 |
| Shares Outstanding (Basic) | 206.43M |
| Shares Outstanding (Diluted) | 209.80M |
Key Highlights
- 1Total revenues for the second quarter of fiscal year 2012 increased by 3.6% to $1.991 billion compared to the prior year, driven by volume increases (5.7%) partially offset by price decreases (1.1%) and unfavorable foreign currency translation (1.0%).
- 2Net income for the quarter decreased to $291 million from $312 million in the prior year, with diluted earnings per share from continuing operations remaining flat at $1.38, though impacted by foreign currency fluctuations.
- 3The Medical segment saw a 4.1% revenue increase to $1.021 billion, driven by Diabetes Care and Pharmaceutical Systems, while the Diagnostics segment grew 4.1% to $630 million, boosted by Preanalytical Systems.
- 4The Biosciences segment experienced slower growth of 1.3% to $340 million, impacted by reduced research funding in the U.S. and increased competition.
- 5The company completed the acquisition of KIESTRA Lab Automation BV for $59.5 million, aimed at enhancing its lab automation solutions within the Diagnostics segment.
- 6Cash generated from continuing operations was $610 million for the first six months of fiscal year 2012, demonstrating solid operational cash flow.
- 7BDX repurchased approximately $1 billion of its common stock and paid $188 million in dividends during the first six months of the fiscal year, returning value to shareholders.